002422 科伦药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入11,827,1029.52%21,453,92919,038,21617,277,40816,464,201
减:营业总成本9,235,4660.92%18,277,36317,223,48416,290,48115,745,366
    其中:营业成本5,460,3017.95%10,205,5359,040,1587,660,1527,532,912
               财务费用27,344-83.52%233,761479,834505,647592,380
               资产减值损失(26,047)-44.15%(130,551)(44,113)(50,428)(57,488)
公允价值变动收益5,46567.43%14,6669,8614,828421
投资收益213,75924.71%358,882234,580214,82994,825
    其中:对联营企业和合营企业的投资收益208,62819.85%352,105228,194127,30386,832
营业利润2,911,94254.86%3,654,1432,195,1421,319,8431,009,962
利润总额2,865,06754.38%3,580,4262,067,9191,177,616955,031
减:所得税费用649,288134.70%933,787363,697309,499163,554
净利润2,215,77940.31%2,646,6391,704,221868,117791,477
减:非控股权益415,668136.92%190,527(1,103)(234,438)(37,909)
股东净利润1,800,11128.24%2,456,1121,705,3241,102,554829,386

市场价值指针
每股收益 (元) *1.15018.56%1.6901.2200.7800.580
每股派息 (元) *0.260--0.8000.6160.4260.319
每股净资产 (元) *13.92826.22%13.00910.8649.7219.383
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容